瑞舒伐他汀对高胆固醇血症患者的降脂疗效及对血管内皮舒张功能的影响

Effect of Lowering Blood Lipid of Rosuvastatin on Patients with Hypercholesterolemia and Improving Diastolic Function of Vascular Endothelium

目的:探讨瑞舒伐他汀对高胆固醇血症患者的降脂疗效及对血管内皮舒张功能(FMD)的影响。方法:选择我院92例高胆固醇血症患者作为实验组并给予瑞舒伐他汀治疗,另选择同期来我院参加健康体检的健康志愿者42例作为对照组,检测治疗前(T0),以及治疗1个月(T1)、2个月后(T2)的血脂水平及肱动脉FMD和非依赖性血管内皮舒张功能(NMD),并对其治疗的不良反应情况进行统计分析。结果:治疗前,实验组患者血浆中TC、TG和LDL-C水平明显高于对照组,而HDL-C水平显著低于对照组,且差异均具有统计学意义(P<0.05)。相对于T0,实验组患者T1和T2血浆中TC、TG和LDL-C水平明显下降,而HDL-C水平显著升高,且差异均具有统计学意义(P<0.05)。患者T2时血浆中TC和LDL-C水平明显低于T1的水平(P<0.05),而TG和HDL-C水平与T1之间的差异无统计学意义(P>0.05);治疗前,实验组患者的FMD值明显低于对照组的健康志愿者(P<0.05)。经过瑞舒伐他汀干预2个月后,实验组患者T2时FMD值明显高于T0(P<0.05),而T2的NMD与T0之间的差异无统计学意义(P>0.05);治疗期间并未出现严重的不良反应。结论:瑞舒伐他汀对老年高胆固醇血症患者降脂效果显著,且有改善FMD的作用。

Objective： To explore efficacy of lowering blood lipid of rosuvastatin on patients with hypercholesterolemia and its improving flow-mediated dilation（FMD）. Methods： A total of 92 elderly patients with hypercholesterolemia were chosen as experimental group, who were treated with rosuvastatin; in addition, 42 healthy volunteers, as control group. The levels of lipid and FMD and non-mediated dilation（NMD） of brachial artery were detected before treatment（T0）, and 1 month after treatment（T1）, 2 months（T2）; meanwhile,the adverse reactions of treatment situation were analyzed. Results： Before treatment, the levels of TC, TG, LDL-C in the serum of patients in the experimental group were obviously higher than those in the control group, while the level of HDL-C was significantly lower than that in the control group, the differences were statistically significant（P〈0.05）. Compared with T0, levels of TC, TG, LDL-C of patients in the experimental group at T1 and T2 were declined obviously, while the HDL-C level increased, the differences were statistically significant（P〈0.05）. The levels of TC and LDL-C of the patients at T2 were significantly lower than at T1（P〈0.05）, but the differences of the levels of TG and HDL-c between T1 and T2 had no statistical significance（P〈0.05）. Before treatment, the value of FMD in the experimental group was lower than that in the control group significantly（P〈0.05）. After 2 months of rosuvastatin intervention, the value of FMD of the patients in the experimental group at T2 was significantly better than at T0（P〈0.05）, while differences of NMD between T2 and T0 had no statistical significance（P〉0.05）. There were no serious adverse reactions during the treatment. Conclusion： Rosuvastatin has significant effect of lowering blood lipid in the treatment of patients with hyperlipidemia, and can improve the FMD.